Literature DB >> 6311790

Randomized study of ceftazidime versus gentamicin plus cefotaxime for infections in severe granulocytopenic patients.

B E de Pauw, F Kauw, H Muytjens, K J Williams, T Bothof.   

Abstract

A randomized study of gentamicin plus cefotaxime versus ceftazidime alone was performed in 87 patients, with a neutrophil count of less than 1000/mm3 at the start of the treatment. The overall cure rate for the ceftazidime group was 71% and for the gentamicin plus cefotaxime 47%. This difference was shown to be statistically significant at a level of P less than 0.05. The cure rates for the microbiologically proven infections were 90 and 63% respectively. Serious adverse effects, causing preliminary withdrawal of therapy, have not been observed.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6311790     DOI： 10.1093/jac/12.suppl_a.93

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  22 in total

1.  Comparison of antimicrobial efficacy of a fixed dose combination of ceftazidime + sulbactam with ceftazidime and sulbactam alone against five bacteria.

Authors:  S M Shrivastava; S K Shukla; M Chaudhary
Journal:  Folia Microbiol (Praha)       Date:  2009-11-24       Impact factor: 2.099

2.  Randomized prospective study of ceftazidime versus ceftazidime plus cephalothin in empiric treatment of febrile episodes in severely neutropenic patients.

Authors:  C S Verhagen; B de Pauw; T de Witte; J Janssen; K Williams; P de Mulder; T Bothof
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

3.  Treatment of Pseudomonas aeruginosa septicemia in neutropenic patients with ceftazidime.

Authors:  B E de Pauw; T de Witte; J T Janssen; C Haanen
Journal:  Eur J Clin Microbiol       Date:  1985-04       Impact factor: 3.267

4.  A randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients.

Authors:  B de Pauw; K Williams; J de Neeff; T Bothof; T de Witte; R Holdrinet; C Haanen
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

Review 5.  Empirical antibiotic therapy in the febrile neutropenic cancer patient: clinical efficacy and impact of monotherapy.

Authors:  J W Hathorn; M Rubin; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

6.  [Comparison of the effectiveness of ceftazidime and cefazolin/tobramycin in patients with inflammatory diseases of the lower respiratory tract].

Authors:  N Vetter; H Feist; C Armbruster; M Drlicek
Journal:  Infection       Date:  1987       Impact factor: 3.553

7.  [Results of several different controlled studies with ceftazidime in the treatment of infections in immunosuppressed patients].

Authors:  B E de Pauw
Journal:  Infection       Date:  1987       Impact factor: 3.553

8.  Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia.

Authors:  S Daenen; Z Erjavec; D R Uges; H G De Vries-Hospers; P De Jonge; M R Halie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

9.  Ceftazidime does not enhance cyclosporin-A nephrotoxicity in febrile bone marrow transplantation patients.

Authors:  C Verhagen; B E de Pauw; T de Witte; R S Holdrinet; J T Janssen; K J Williams
Journal:  Blut       Date:  1986-10

10.  Three-step empiric treatment for severely neutropenic patients with fever: ceftazidime--vancomycin--amphotericin B.

Authors:  H Koeppler; K H Pflueger; R Seitz; K Havemann
Journal:  Infection       Date:  1989 May-Jun       Impact factor: 3.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.